Chair of Epidemiology, LMU München, UNIKA-T Augsburg, Augsburg, Germany.
Independent Research Group Clinical Epidemiology, Helmholtz Zentrum München, German Research Center for Environmental Health, Munich, Germany.
Addict Biol. 2021 Nov;26(6):e13020. doi: 10.1111/adb.13020. Epub 2021 Feb 12.
Cannabis has effects on the insulin/glucose metabolism. As the use of cannabis and the prevalence of type 2 diabetes increase worldwide, it is important to examine the effect of cannabis on the risk of diabetes. We conducted a Mendelian randomization (MR) study by using 19 single-nucleotide polymorphisms (SNPs) as instrumental variables for lifetime cannabis use and 14 SNPs to instrument cannabis use disorder and linking these to type 2 diabetes risk using genome-wide association study data (lifetime cannabis use [N = 184,765]; cannabis use disorder [2387 cases/48,985 controls], type 2 diabetes [74,124 cases/824,006 controls]). The MR analysis suggested no effect of lifetime cannabis use (inverse-variance weighted odds ratio [95% confidence interval] = 1.00 [0.93-1.09], P value = 0.935) and cannabis use disorder (OR = 1.03 [0.99-1.08]) on type 2 diabetes. Sensitivity analysis to assess potential pleiotropy led to no substantive change in the estimates. This study adds to the evidence base that cannabis use does not play a causal role in type 2 diabetes.
大麻会影响胰岛素/葡萄糖代谢。随着大麻的使用和 2 型糖尿病的全球流行率增加，研究大麻对糖尿病风险的影响非常重要。我们通过使用 19 个单核苷酸多态性 (SNP) 作为终生大麻使用的工具变量，并使用 14 个 SNP 来检测大麻使用障碍，并利用全基因组关联研究数据将这些与 2 型糖尿病风险联系起来（终生大麻使用 [N=184765]；大麻使用障碍 [2387 例/48985 例对照]，2 型糖尿病 [74124 例/824006 例对照]）。MR 分析表明，终生大麻使用（逆方差加权比值 [95%置信区间] = 1.00 [0.93-1.09]，P 值=0.935）和大麻使用障碍（比值比 [99%置信区间] = 1.03 [0.99-1.08]）对 2 型糖尿病没有影响。为评估潜在的混杂因素而进行的敏感性分析并没有导致估计值发生实质性变化。这项研究增加了证据基础，表明大麻使用不会在 2 型糖尿病中起因果作用。
